Nanomedicines are solving the drug delivery problem in kidney disease. The next step: bridging the translational gap to advance these technologies into the clinic.
- GenAI: The Muscle Behind Strong Regulatory Intelligence For Combination Products
- Regulatory Precedents For Drug Delivery: Uncovering Clues To Successful Submissions
- Microneedle Delivery Of Telomerase Protects Skin From Radiation-Induced DNA Damage
- Benchmarking RNA Delivery Performance: Toward Standardized Metrics For Translational Success
- Rethinking Product Development Through Lipid-Based Formulations
- Overcoming Lung Tumor Barriers: Nanoparticle Delivery Strategies For Pulmonary Cancers
- Advances In Endometrial-Targeted Drug Delivery In Women's Health
- RNA Delivery Technologies: Industrial Applications And Emerging Innovations
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Selecting A Vial Container Closure System With The DeltaCube™ Modeling Platform
Understand a system approach that facilitates data-driven selection and optimization of vial container closure system components.
-
Why 'Off-The-Shelf' Devices Do Not Circumvent Design Controls
Utilizing off-the-shelf (OTS) devices for drug delivery can offer significant advantages to development programs in timeline and risk mitigation. Understand the design control responsibilities of a sponsor when using OTS devices.
-
Choosing A Formulation And Process Approach To OCR Products
Do you want to develop an oral controlled release (OCR) product? Understand the options and their ramifications as the first step toward devising a plan.
-
Spray Drying To Enable New Inhaled Drug Products
The formulation and spray drying process can help manufacture a stable, highly respirable powder and deliver products that require a high drug load, a biologic, or rapid onset therapeutic.
-
Combining Powdose® And Diffucaps® For Precise Solid Oral Dosing
Combining POWDOSE® and Diffucaps® enables precise, individualized solid oral dosing—improving drug delivery, patient compliance, and therapeutic outcomes in personalized medicine applications.
-
Using 505(B)(2) To Streamline Approval Of Combination Products
In recent years, the quantity of approvals for products and 505(b)(2) applications has risen, causing developers to map out their regulatory strategy as early as possible.
-
Deploying A Circular Economy For Medical Devices
A circular economy prioritizes sustainability throughout the supply chain by eliminating waste, circulating products and materials, and regenerating nature.
-
Unlocking New Possibilities For Treating Rare Genetic Diseases
With over 7,000 rare diseases, the potential for nanomedicine to revolutionize treatment is immense. While polymer nanoparticles hold great promise, several challenges remain.
-
De-Risking The Transition From Vial To Drug-Device Combination Product
When transitioning from a vial to a combination product system, the best approach is to have a holistic de-risk strategy with an intentional focus on the patient, the plan, and the product.
-
Developing A Multi-Drug Combination, Antiparasitic Drug For Dogs
Discover how it worked to manufacture clinical supplies of flavored tablets with multiple APIs in just six months while ensuring content uniformity and stability.
TOM'S TAKES ON DRUG DELIVERY
TALKING WITH TOM VIDEOCASTS
DELIVERED BY DEGRAZIO
-
4 Opportunities For Advancing Drug Delivery
In this article, Fran DeGrazio identifies four prime opportunities for drug delivery developers to move the dial of innovation into 2026 and beyond. These avenues for advancement include diagnostics, patient tolerability, microdosing, and analytical methodologies.

